Germany's SCHERING (pharmaceuticals) is to sell 50% of its anti-cancer genetic research subsidiary METAGEN to the British venture-capital firm APAX for 42 million euro. The subsidiary's board will hold a 6.5% stake and SCHERING will retain 43.5%.
